Telomir Pharmaceuticals, Inc. Common Stock
TELOAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Sep 17, 2026 | Maxim Group | $4.00(+254%) | $1.13 | TheFly |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 6, 2026 | $-0.01 | $-0.08 | — | $500.0K |
| Aug 13, 2026 | $-0.79 | $-0.07 | — | — |
| May 13, 2026 | $-0.03 | $-0.07 | — | — |
| Mar 17, 2026 | $-0.06 | $-0.07 | — | — |
| Nov 10, 2025 | $-0.03 | $-0.07 | — | — |
| Aug 14, 2025 | $-0.17 | $-0.08 | — | — |
| May 14, 2025 | $-0.07 | $-0.10 | — | — |
| Feb 4, 2025 | $-0.10 | $-0.05 | $18.8M | — |
News
In matched multi-center cohorts, Telo Genomics is expanding comparative evaluation of blood-based TELO-MRD against Adaptive Biotechnologies' clonoSEQ next-generation sequencing MRD testing. Vancouver, British Columbia--(Newsfile Corp. - October 29, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests based on three-dimensional analysis of telomeres (which are the ends of chromosomes), today anno…
MIAMI, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, today announced an approximately $5.6 million private investment in public equity (PIPE) financing through the issuance of common stock, without any accompanying investor warrants or convertible securities. The financing includes an additional $1.0 million investment from billiona…
In matched Cleveland Clinic and Jewish General Hospital samples, blood-based TELO enumeration detected circulating plasma cells in all Adaptive clonoSEQ-positive cases reviewed and in a series of clonoSEQ-negative or non-evaluable samples; previously reported EuroFlow comparison data are also summarized. Vancouver, British Columbia--(Newsfile Corp. - September 29, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic…
MIAMI, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, today announced the peer-reviewed publication of new preclinical research showing that Telomir-Zn significantly improved visual function, restored retinal structure, and reduced mitochondrial oxidative stress in a model of age-related macular degeneration (AMD).
MIAMI, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, announced new research findings from The Ohio State University College of Veterinary Medicine demonstrating that Telomir-Zn produces inhibition of cell growth across human and canine osteosarcoma models.
Shares of Telomir Pharmaceuticals, Inc. (NASDAQ: TELO - Get Free Report) were down 3.4% during mid-day trading on Tuesday. The company traded as low as $1.13 and last traded at $1.13. 27,578 shares traded hands during trading, a decline of 74% from the average daily volume of 104,128 shares. The stock had previously closed at